Literature DB >> 30096720

Mechanistic Pathways of Selenium in the Treatment of Graves' Disease and Graves' Orbitopathy.

Michele Marinò1, Giovanna Rotondo Dottore1, Marenza Leo1, Claudio Marcocci1.   

Abstract

Based on the role of oxidative stress in the pathogenesis of Graves' hyperthyroidism and Graves' orbitopathy, the use of the antioxidant agent selenium has been proposed and several studies on the subject have been conducted, both in vitro and in vivo. Whereas a true benefit related to the use of selenium in patients with Graves' hyperthyroidism has been questioned, its use in patients with mild Graves' orbitopathy is generally believed to be beneficial because of which selenium has entered in the clinical practice for this eye condition. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30096720     DOI: 10.1055/a-0658-7889

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  6 in total

Review 1.  Selenium in thyroid disorders - essential knowledge for clinicians.

Authors:  Kristian Hillert Winther; Margaret Philomena Rayman; Steen Joop Bonnema; Laszlo Hegedüs
Journal:  Nat Rev Endocrinol       Date:  2020-01-30       Impact factor: 43.330

2.  Changes of autoantibodies and intercellular adhesion molecule-1 in patients with Graves disease after clinical treatment.

Authors:  Jing Zhang; Rongrong Zhang; Zhenhong Zhao
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

Review 3.  Orbital diseases mimicking graves' orbitopathy: a long-standing challenge in differential diagnosis.

Authors:  M Marinò; I Ionni; G Lanzolla; A Sframeli; F Latrofa; R Rocchi; C Marcocci
Journal:  J Endocrinol Invest       Date:  2019-11-05       Impact factor: 5.467

Review 4.  Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy.

Authors:  Giulia Lanzolla; Guia Vannucchi; Ilaria Ionni; Irene Campi; Federica Sileo; Elisa Lazzaroni; Michele Marinò
Journal:  Front Endocrinol (Lausanne)       Date:  2020-01-22       Impact factor: 5.555

Review 5.  The Role of Oxidative Stress and Therapeutic Potential of Antioxidants in Graves' Ophthalmopathy.

Authors:  Tzu-Yu Hou; Shi-Bei Wu; Hui-Chuan Kau; Chieh-Chih Tsai
Journal:  Biomedicines       Date:  2021-12-10

6.  Relative selenium insufficiency is a risk factor for developing severe Graves' orbitopathy: a case-control study.

Authors:  Mingkwan Lumyongsatien; Unnkade Bhaktikamala; Pennung Thongtong; Sunisa Sintuwong; Ornvenus Nimitwongsakul; Jugchawin Kanokkantapong; Krit Pongpirul
Journal:  BMJ Open Ophthalmol       Date:  2021-05-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.